Bladder Urothelial Carcinoma
Therapeutic response
Precision oncology relationships for therapeutic response involving this cancer type.
| Organization(s) | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| EMA (1) FDA (1) | FGFR3 p.R248C | Bladder Urothelial Carcinoma | Erdafitinib | |
| EMA (1) FDA (1) | FGFR3 p.S249C | Bladder Urothelial Carcinoma | Erdafitinib | |
| EMA (1) FDA (1) | FGFR3 p.G370C | Bladder Urothelial Carcinoma | Erdafitinib | |
| EMA (1) FDA (1) | FGFR3 p.Y373C | Bladder Urothelial Carcinoma | Erdafitinib | |
| EMA (1) FDA (1) | FGFR3::TACC3 | Bladder Urothelial Carcinoma | Erdafitinib | |
| EMA (1) | PD-L1 (CPS) >= 10 | Bladder Urothelial Carcinoma | Pembrolizumab | |
| EMA (1) | PD-L1 >= 1% | Bladder Urothelial Carcinoma | Nivolumab | |
| EMA (1) | PD-L1 >= 5% | Bladder Urothelial Carcinoma | Atezolizumab | |
| EMA (1) | FGFR2::BICC1 | Bladder Urothelial Carcinoma | Erdafitinib | |
| EMA (1) | FGFR2::CASP7 | Bladder Urothelial Carcinoma | Erdafitinib | |
| EMA (1) | FGFR3::BAIAP2L1 | Bladder Urothelial Carcinoma | Erdafitinib |